NCT02547714

Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A

A Multi-center, Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety for 16 Weeks in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to assess the efficacy and safety of secukinumab at Week 16 based on psoriasis area and severity index (PASI) 75 in subjects who had inadequate response to cyclosporine A.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Secukinumab (AIN457)	Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.

Timeline

• Start date: 2015-06-16
• Primary completion: 2016-05-02
• Completion: 2016-05-02
• First posted: 2015-09-11
• Last updated: 2017-09-11
• Results posted: 2017-06-27

Locations

11 sites across 1 country: Japan